Retraction: Activation of Toll-Like Receptor-9 Promotes Cellular Migration via Up-Regulating MMP-2 Expression in Oral Squamous Cell Carcinoma (PLoS ONE (2014) 9: 3 (e92748) DOI: 10.1371/journal.pone.0092748);Activation of Toll-like receptor-9 promotes cellular migration via up-regulating MMP-2 expression in oral squamous cell carcinoma

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Ruan, Min ^a   Zhang, Zun ^b   Li, Siyi ^a   Yan, Min ^a   Liu, Shengwen ^a   Yang, Wenjun ^a   Wang, Lizheng ^a   Zhang, Chenping ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR AP 1;

ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; DNA BINDING; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME RELEASE; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR MECHANICS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR INVASION; UPREGULATION;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME ACTIVATION; GENE EXPRESSION; HUMANS; MATRIX METALLOPROTEINASE 2; MOUTH NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 9; TRANSCRIPTION FACTOR AP-1;

EID: 84899118522     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0288029     Document Type: Erratum

References (35)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108. (Pubitemid 40372904)
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC Cancer Base No. 10. International Agency for Research on Cancer: Available: http://globocan.iarc.fr. Accessed 2012 Jul 20.
3. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, et al. (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091-2098. (Pubitemid 37464533)
4. Myoung H, Kim MJ, Hong SD, Lee JI, Lim CY, et al. (2002) Expression of membrane type I-matrix metalloproteinase in oral squamous cell carcinoma. Cancer Lett 185:201-209.
5. O'Neill LA (2002) Signal transduction pathways activated by the IL-1 receptor/Toll-like receptor super family. Curr Top Microbiol Immunol 270:47-61.
6. Takeda K, Akira S (2005) Toll-like receptors in innate immunity. Int Immunol 17: 1-14.
7. Rakoff-Nahoum S, Medzhitov R (2009) Toll-like receptors and cancer. Nat Rev Cancer 9:57-63.
8. Chen R, Alvero AB, Silasi DA, Mor G (2007) Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signalingpathway. Am J Reprod Immunol 57:93-107. (Pubitemid 46099804)
9. Xie W, Wang Y, Huang Y, Yang H, Wang J, et al. (2009) Toll-like receptor 2 mediates invasion via activating NF-kappaB in MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun 379:1027-1032.
10. Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, et al. (2006) Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res 4:437-447. (Pubitemid 44197039)
11. Hua D, Liu MY, Cheng ZD, Qin XJ, Zhang HM, et al. (2009) Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cellinvasion, survival, and tumorigenicity. Mol Immunol 46:2876-2884.
12. Ilvesaro JM, Merrell MA, Swain TM, Davidson J, Zayzafoon M, et al. (2007) Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate 67:774-781. (Pubitemid 46709446)
13. Killeen SD, Wang JH, Andrews EJ, Redmond HP (2009) Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-κB-dependent activation of the urokinase plasminogen activator system. Br J Cancer 100:1589-1602.
14. Guo H, Chen Y, Hu X, Qian G, Ge S, et al. (2013) The regulation of toll-like receptor 2 by miR-143 suppresses the invasion and migration of a subset of human colorectal carcinoma cells. Molecular Cancer 12:77.
15. O'Neill LA, Golenbock D, Bowie AG (2013) The history of Toll-like receptors - redefining innate immunity. Nat Rev Immunol 13:453-460.
16. Ruan M, Zun Z, Siyi L, Wenjun Y, Lizheng W, et al. (2011) Increased expression of Toll-like receptor-9 has close relation with tumour cell proliferation in oral squamous cell carcinoma. Arch Oral Biol 56: 877-884.
17. Min R, Siyi L, Wenjun Y, Shengwen L, Ow A, et al. (2012) Toll-like receptor-9 agonists increase cyclin D1 expression partly through activation of activator protein-1 in human oral squamous cell carcinoma cells. Cancer Sci 103:1938-1945.
18. Zhong LP, Pan HY, Zhou XJ, Ye DX, Zhang L, et al. (2008) Characteristics of a cancerous cell line, HIOEC-B(a)P-96, induced by benzo(a)pyrene from human immortalized oral epithelial cell line. Arch Oral Biol 53:443-452.
19. Ruan M, Ji T, Yang WJ, Duan WH, Zhou XJ, et al. (2008) Growth Inhibition and Induction of Apoptosis in Human Oral Squamous Cell Carcinoma Tca-8113 Cell Lines by Shikonin was partly through the Inactivation of NF-κB Pathway. Phytother Res 22:407-415.
20. Kaomongkolgit R, Cheepsunthorn P, Pavasant P, Sanchavanakit N (2008) Iron increases MMP-9 expression through activation of AP-1 via ERK/Akt pathway in human head and neck squamous carcinoma cells. Oral Oncol 44:587-594. (Pubitemid 351681968)
21. Toualbi-Abed K, Daniel F, Güller MC, Legrand A, Mauriz JL, et al. (2008) Jun D cooperates with p65 to activate the proximal kB site of the cyclin D1 promoter: role of PI3K/PDK-1. Carcinogenesis 29:536-543. (Pubitemid 351404869)
22. Mantovani A (2009) Cancer: Inflaming metastasis. Nature 457:36-37.
23. Gupta GP, Massague J (2006) Cancer metastasis: building a framework. Cell 127:679-695. (Pubitemid 44781029)
24. Steeg PS (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12:895-904.
25. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174. (Pubitemid 37328786)
26. Kusukawa J, Sasaguri Y, Shima I, Kameyama T, Morimatsu M (1993) Expression of matrix metalloproteinase-2 related to lymph node metastasis of oral squamous cell carcinoma. A clinicopathologic study. Am J Clin Pathol 99: 18-23. (Pubitemid 23030665)
27. Li J, Guo Y, Feng X, Wang Z, Wang Y, Deng P, et al. (2005) Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma. Oral Oncol 41:283-293.
28. Katayama A, Bandoh N (2004) Expressions of Matrix Metalloproteinases in Early-Stage Oral Squamous Cell Carcinoma as Predictive Indicators for Tumor Metastases and Prognosis. Clin Cancer Res 10:634-640. (Pubitemid 38174003)
29. Bergman MR, Cheng S, Honbo N, Piacentini L, Karliner JS, et al. (2003) A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers. Biochem J 369:485-496. (Pubitemid 36246232)
30. Philip S, Kundu GC (2003) Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha/IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem 278:14487-14497. (Pubitemid 36800002)
31. Kawai T, Akira S (2006) TLR signaling. Cell Death and Differentiation 13: 816-825.
32. Yang XC, Wang X, Luo L, Dong DH, Yu QC, et al. (2013) RNA interference suppression of A100A4 reduces the growth and metastatic phenotype of human renal cancer cells via NF-kB-dependent MMP-2 and bcl-2 pathway. Eur Rev Med Pharmacol Sci 17:1669-1680.
33. Hsieh YS, Chu SC, Yang SF, Chen PN, Liu YC, et al. (2007) Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2. Carcinogenesis 28:977-987.
34. Hess J, Angel P, Schorpp-Kistner M (2004) AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 117:5965-5973. (Pubitemid 40123963)
35. Perkins ND (2007) Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8:49-62.